Zhonghua Zhong Liu Za Zhi. 2024 Mar 22;46(0):285-295. doi: 10.3760/cma.j.cn112152-20240206-00067.
With the advancement of prostate cancer (PCa) diagnosis and treatment technology, the 5-year survival rate has remarkably increased, and PCa has entered the era of chronic disease management. Medical castration therapy remains the cornerstone treatment option for PCa patients, and run throughout the various stages of patient treatment. The disease progression, treatment-related adverse reactions and related complications of PCa patients after medical castration have become a major problem in the long-term management of PCa patients, affecting the survival and quality of life of patients. In addition to focus on the disease management of prostate patients during diagnosis and treatment, patients should be closely followed up after medical castration, especially for those at the critical stage of disease treatment. Testosterone or other indicators should be monitored at important nodes of the disease (the point of initiation disease phase and the point of treatment switch) to avoid missing the optimal treatment window. Follow-up management of PCa should take into account the characteristics of the treatment stage of the disease (disease stage, previous symptoms, prognostic factors and treatment strategy) and patients' own demands, and personalized follow-up strategies should be recommended to better increase patients' treatment compliance and improve patients' prognosis. Currently, there is a lack of guidelines or consensus on the management on the follow-up and quality of life of PCa patients after medical castration in China. Therefore, the Chinese Prostate Cancer Consortium has organized domestic experts to formulate this consensus, with the aim of providing a reference for the management on the follow-up and quality of life of PCa patients receiving medical castration therapy, and to further improve the prognosis and quality of life of PCa patients in China.
随着前列腺癌（PCa）诊断和治疗技术的进步，5年生存率显著提高，PCa已进入慢性病管理时代。药物去势治疗仍然是PCa患者的基石治疗选择，并贯穿患者治疗的各个阶段。PCa患者药物去势后的疾病进展、治疗相关不良反应及相关并发症已成为PCa患者长期管理中的主要问题，影响患者的生存和生活质量。除了在诊断和治疗期间关注前列腺患者的疾病管理外，药物去势后应对患者进行密切随访，尤其是处于疾病治疗关键阶段的患者。应在疾病的重要节点（疾病起始阶段和治疗转换点）监测睾酮或其他指标，以避免错过最佳治疗窗口。PCa的随访管理应考虑疾病治疗阶段的特点（疾病分期、既往症状、预后因素和治疗策略）以及患者自身需求，推荐个性化的随访策略，以更好地提高患者的治疗依从性并改善患者预后。目前，我国在PCa患者药物去势后的随访及生活质量管理方面缺乏指南或共识。因此，中国前列腺癌联盟组织国内专家制定本共识，旨在为接受药物去势治疗的PCa患者的随访及生活质量管理提供参考，进一步改善我国PCa患者的预后和生活质量。
